Quick answer: Vilon is a market name for the dipeptide Lys-Glu (KE, under 300 Da) studied by Khavinson and colleagues. Published work is mostly cell cultures and docking models from one network of laboratories, so it is early evidence. V8 does not sell Vilon; this page is research background only.
A two-residue peptide with a brand-style name
Vilon is the name used in the research-peptide market for the dipeptide lysine-glutamate, written Lys-Glu or KE. It belongs to the family of ultrashort peptides that Vladimir Khavinson and colleagues in St. Petersburg call peptide bioregulators. It is the shortest member of that family most buyers will meet, and it is often listed next to the tripeptides covered in our pinealon and Cartalax guides.
This page explains what the molecule is, what the published laboratory papers report, how far that evidence goes, and what a certificate should show for such a reagent. It is background for laboratory research use only. V8 Peptides does not sell Vilon, and nothing here describes an effect or use in people or animals.
What the molecule is
KE has just two amino acids joined by one peptide bond. Lysine carries a positively charged side chain and glutamate a negatively charged one, so the dipeptide is small, polar and carries both charges at neutral pH. Its mass is under 300 daltons, well below the multi-thousand dalton peptides described in our Selank and Semax guides.
At that size a molecule gives an analytical method very little to work with. There is no long chain to fragment, and it behaves like a free amino acid on many chromatography columns. A label that only gives the market name does not tell you what is in the vial. The sequence and a measured mass are what identify it, and they are also what separate KE from its reverse, EK, and from a simple mixture of free lysine and glutamate.
Side-by-side comparison
| Item | What is reported | Source |
|---|---|---|
| Sequence | Lys-Glu (KE), a dipeptide under 300 Da | Compound definition |
| Peptide vs free amino acids | Dipeptide stimulated spleen-cell culture growth; the amino acid mixture inhibited it | Khavinson 2015 |
| DNA interaction, model | Docking placed KE in the minor groove with higher energy than the free amino acids | Khavinson 2015 |
| Thymus cell culture | Higher CD5 expression for two dipeptides, including Vilon and an analogue | Sevostianova 2013 |
| Stem-cell aging cultures | Changed expression of IGF1, FOXO1, TERT, TNKS2 and NFkB, depending on model | Ashapkin 2020 |
| Neuronal markers | Peptide mixture including KE raised GAP43 and Nestin in stem cells | Caputi 2019 |
| Independent replication | Limited; mostly one network of laboratories | See text |
What the cell-culture papers report
A 2015 paper by Khavinson and colleagues compared Lys-Glu with a mixture of its two amino acids in organotypic cultures of spleen cells. The authors reported that the dipeptide stimulated proliferation of the cultured cells, while the mixture of the free amino acids inhibited growth. They concluded that the peptide bond itself matters for the observed activity.
A 2013 paper from the same network studied two dipeptides, one described as Vilon and its analogue, in cultured thymus cells from humans and rats. The authors reported higher expression of the lymphocyte marker CD5 and changes in the differentiation of T-cell precursors in culture.
A 2020 paper by Ashapkin and colleagues exposed human mesenchymal stem cell cultures, aged by two different methods, to AED, KED and KE at nanomolar concentrations. They reported changes in the expression of genes including IGF1, FOXO1, TERT, TNKS2 and NFkB, and noted that results differed between the two aging models. In 2019, Caputi and colleagues reported that a mixture of four short peptides including KE raised markers of neuronal differentiation in human periodontal ligament stem cells, with KED alone producing part of the effect.
Every one of these is a cell-culture measurement under defined conditions. They describe changes in markers in a dish, and cannot be read as effects in an organism.
The proposed mechanism
The group proposes that very short peptides can enter cells and reach the nucleus, where they interact with DNA and affect which genes are read. In the 2015 paper, molecular docking calculations placed Lys-Glu along the minor groove of DNA, and the calculated interaction energy was higher for the dipeptide than for the separate amino acids. A 2022 review by Ilina and colleagues puts the idea in the wider area of epigenetic regulation by ultrashort peptides.
A docking result is a computer model. It shows what is energetically possible, not that a dipeptide reaches a specific gene inside a living cell. A claim that a two-residue peptide crosses membranes, enters the nucleus and acts on DNA is unusual and needs testing in independent laboratories with matching controls, such as the reversed sequence and the free amino acid mixture.
How strong is the evidence?
It is early and narrow. Most of the papers come from one network of laboratories, several appear in regional journals, and the models are limited to a few cell types. Some work includes outside collaborators, such as the Italian stem-cell group in the 2019 paper, which is a point in its favor.
None of that makes the work uninteresting. It means a study design should regard the reports as hypotheses to test, include controls, and state the model and readout clearly rather than quote a headline from a product page.
What a certificate should show for a dipeptide reagent
For a dipeptide, identity matters most. Look for the sequence Lys-Glu, a measured mass next to the expected value, and a lot identifier and date. For background on reading these documents, see understanding HPLC purity, HPLC vs. mass spectrometry and how to read a COA.
What V8's lab reports contain. The lab reports published for V8 lots, issued by Accumark Labs, show HPLC purity, identity and measured quantity and, for most lots, endotoxin (LAL) and a rapid PCR sterility screen. See the COA library for the report on a specific lot.
Ask how HPLC purity was measured. A molecule this polar can elute at the solvent front, which makes a purity percentage less informative unless the method was tuned for it. Counter-ion, salt and water content are a large share of the weight of such a small molecule, which matters when a laboratory prepares a stock solution by weight.
For cell work, an endotoxin result and a sterility statement matter as much as purity. More buyer-side guidance is in choosing a peptide supplier and red flags when buying research peptides.
Handling and record keeping
Keep lyophilized peptide cold, dry and protected from light, and write the opening date on the vial. Plan aliquots before opening, because short hydrophilic peptides can pick up moisture quickly. General guidance is in how long reconstituted peptides last and what a normal vial looks like. For concentration arithmetic use the reconstitution calculator.
In the notebook, record the compound name, sequence, lot, supplier, certificate date and storage conditions, so a later reader can tie any result to a defined reagent. The certificates of analysis page shows what V8 publishes for the products it sells.
Certificate checklist for a dipeptide
| Field | What to look for | Why it matters |
|---|---|---|
| Sequence | Lys-Glu written out | Separates KE from EK or a free amino acid mixture |
| Measured mass | Value beside the expected mass | Identity of a very small molecule |
| HPLC method | Column and gradient stated | Polar peptides can elute at the solvent front |
| Lot and date | Identifier matching the vial | Ties a result to one reagent |
| Endotoxin and sterility | Reported values | Relevant to cell-based work |
Vilon belongs to the same short-peptide family as Epithalon, which V8 lists as a research peptide with a certificate of analysis; the sibling explainers for Pinealon and Cartalax use the same evidence framework.
Frequently asked questions
What is Vilon?
A market name for the dipeptide Lys-Glu (KE), studied by Khavinson and colleagues as one of their short peptide bioregulators.
How big is the molecule?
Under 300 daltons, which is about as small as a peptide gets and limits what an analytical method can show.
What kinds of studies exist?
Cell cultures, molecular docking models and reviews, mostly from one network of laboratories.
Does the research show effects in people?
This guide makes no such claim. It covers laboratory research and is not evidence of any effect in people or animals.
Why does the peptide bond matter in the papers?
One paper compared the dipeptide with a mix of its free amino acids and reported different results in the same culture.
Is Vilon the same as KED or Cartalax?
No. KED is the tripeptide Lys-Glu-Asp and Cartalax is Ala-Glu-Asp. They have different sequences and masses.
Why does HPLC need care for a dipeptide?
A very polar molecule can elute near the solvent front, so the method used affects how a purity figure should be read.
How can I check I have KE and not another molecule?
Read the sequence and the measured mass on the certificate and compare them with the expected value.
Is the evidence independent?
Mostly not. Most papers come from one network of laboratories, with some outside collaboration.
Does V8 sell Vilon?
No. This page is research background and is not a product listing.
What should I record for each vial of any research peptide?
The exact compound name, sequence, lot identifier, certificate date, supplier, storage conditions and the date the vial was opened.
References
- Ashapkin V, Khavinson V, Shilovsky G, Linkova N, Vanuyshin B. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep. 2020;47(6):4323-4329. doi:10.1007/s11033-020-05506-3. PMID: 32399807.
- Caputi S, Trubiani O, Sinjari B, Trofimova S, Diomede F, Linkova N, Diatlova A, Khavinson V. Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol. 2019;33:2058738419828613. doi:10.1177/2058738419828613. PMID: 30791821.
- Khavinson VKh, Tarnovskaya SI, Lin'kova NS, Chervyakova NA, Nichik TE, Elashkina EV, Chalisova NI. Role of peptide bond in the realization of biological activity of short peptides. Bull Exp Biol Med. 2015;158(4):551-554. doi:10.1007/s10517-015-2805-0. PMID: 25705040.
- Sevostianova NN, Linkova NS, Polyakova VO, Chervyakova NA, Kostylev AV, Durnova AO, Kvetnoy IM, Abdulragimov RI, Khavinson VH. Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells. Bull Exp Biol Med. 2013;154(4):562-565. doi:10.1007/s10517-013-2000-0. PMID: 23486604.
- Ilina A, Khavinson V, Linkova N, Petukhov M. Neuroepigenetic mechanisms of action of ultrashort peptides. Int J Mol Sci. 2022;23(8). PMID: 35457077.
